FDA actions support and strengthen domestic drug manufacturing through regulatory modernization, supply chain resilience, and expanded use of advanced production technologies

FDA policy actions aim to expand domestic drug manufacturing capacity in the United States and reduce vulnerabilities in pharmaceutical supply chains. The focus is on regulatory tools that can speed facility development, encourage modern manufacturing methods, and improve the availability of essential medicines. Domestic production is tied to advanced manufacturing technologies, clearer regulatory pathways, and collaboration with industry to support quality, efficiency, and resilience. These measures matter because manufacturing bottlenecks and overseas dependence can disrupt access to medicines, while stronger US capacity can improve public health preparedness and long term supply security.